news aktuell GmbHnews aktuell GmbH

Green Tech Cluster Styria: Hydrogen Research Map Austria: 18 Institutes and 1 Site - top in Europe

Share
As one of the basic building blocks on the path to climate neutrality, research into green hydrogen technologies is taking off. In Austria, 18 academic and non-academic research institutions are working in this field and have been listed in the H2 Research Map with details of expertise, laboratory facilities and contacts. Styria accounts for 60% of researchers and the Graz University of Technology Campus is among the European leaders in the field.

(Graz, Austria): The EU Green Deal is expected to stimulate highly dynamic and concentrated activity, focused on industrial, grid-friendly and mobile applications for hydrogen, on the path to climate neutrality. The H2 Research Map, that has been collated by the Green Tech Cluster, from information provided by academic and non-academic research institutions in Austria, gives the key focus of research, the size of the laboratory facilities and equipment, and the contact persons for collaboration with commercial enterprises.

Across Austria, a total of 18 institutions, employing 310 (full-time equivalent) hydrogen researchers have been recorded. Styria, in the “Green Tech Valley”, leads with more than 60% of Austria's hydrogen researchers. The Graz University of Technology Campus, housing HyCentA, LEC and BEST with 160 research workers, is not only by far the largest centre for hydrogen research in Austria, it also ranks as one of the top in Europe alongside the likes of Forschungszentrum Jülich. To stay on top of the strong international dynamics, a new gas analysis laboratory was opened.

Contacts

For more information on the H2 Research Map and further Climate Solutions please contact:


Johannes Kohlmaier, Green Tech Cluster
Projectmanager Climate Solutions
Phone: +43 316/40 77 44-14
Mobile:+43 676/57 15 840
kohlmaier@greentech.at

Images

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release

Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized

Digital Subsidiary of Austrian State Printing Company Wins Infrastructure Tender for German EU Digital Identity Wallet22.12.2025 15:12:30 CET | Press release

youniqx Identity, a digital subsidiary of the Austrian State Printing Company (OSD), has won a Europe-wide tender, together with partner companies, for the infrastructure of the German EU Digital Identity Wallet (EUDI-Wallet). EU member states are required by EU regulations to provide a national version of an EU-wide valid EUDI-Wallet by the end of 2026. Citizens will be able to use the EUDI-Wallet to prove their personal identity throughout the EU

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye